Chicago, June 2, 2016 -- Siemens Healthineers -- At the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7 at McCormick Place in Chicago, Siemens Healthineers exhibits its extensive cancer care portfolio, specifically demonstrating solutions for the complex and increasingly common conditions of lung, liver, prostate, and breast cancers. As a pioneer in bringing innovative technologies to market and enabling physicians to deliver high quality patient care, Siemens Healthineers' portfolio spans laboratory diagnostics, imaging, therapy guidance, clinical IT, and services.

The company's recent acquisition of NEO New Oncology AG, a Cologne, Germany-based company, supports the growth of Siemens Healthineers in the rapidly expanding space for molecular diagnostics in oncology and complements its existing offerings in the German market. NEO New Oncology's liquid biopsy test, "NEOliquid," extracts and sequences circulating free tumor DNA in blood samples, allowing for genomic analysis of the tumor and support of targeted therapy decisions.1

"As enablers of exceptional healthcare, we strive to bring healthcare professionals the solutions needed to diagnose and treat even the most complex of cancers," says David Pacitti, President and Head of Siemens Healthineers North America. "Oncology is a key priority for Siemens, and we are strongly committed to providing unique, leading-edge technology solutions."
Lung

Annual lung cancer screening with computed tomography (CT) for high-risk populations/patients has been shown to contribute to a 20% reduction in lung cancer related mortality.2 Siemens Healthineers offers the industry's most comprehensive approach to low-dose CT lung cancer screening using standard low-dose lung protocols on many of its CT scanners. From the SOMATOM Scope 16-slice CT system to the ultra-premium SOMATOM Force, Siemens Healthineers makes low-dose CT lung cancer screening broadly available to customers.

Liver

Patients with locally advanced primary or secondary liver tumors are often not candidates for surgical resection and in most cases have a limited prognosis. In recent years, interventional procedures such as Selective Internal Radiation Therapy (SIRT, also known as radioembolization) have begun to play a more meaningful role in the treatment of these tumors. SIRT treats liver cancer internally through the injection of millions of SIR-Spheres Y-90 resin microspheres – microscopic resin beads manufactured by Sirtex Medical Limited and labelled with radioactive Yttrium-90 (Y-90) – directly into liver tumors via the hepatic vasculature. These microspheres then become lodged in the tumor's blood vessels, enabling high doses of radiation to be targeted directly to liver tumors while sparing healthy parenchyma.

US Press Room Homepage